Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL
Status:
Withdrawn
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This is a phase I study of the combination of volasertib and romidepsin in patients with
relapsed/refractory peripheral T cell lymphoma (PTCL) or stage IIB-IV cutaneous T cell
lymphoma (CTCL). This study will determine the maximum tolerated dose (MTD) of this
combination by treating cohorts of patients at a certain dose combination. The investigators
will use a Bayesian design to determine the dose combination for the next cohort of patients
and to determine the MTD. Overall response rate as well as adverse events will be monitored
and reported.
Phase:
Phase 1
Details
Lead Sponsor:
Anne Beaven, MD
Collaborators:
Boehringer Ingelheim National Comprehensive Cancer Network